Related Experiment Videos
The changes of serum soluble intercellular adhesion molecule-1 after systemic steroid treatment in vitiligo
1Department of Dermatology, College of Medicine, Seoul National University, South Korea.
Insights
Elevated soluble intercellular adhesion molecule-1 (sICAM-1) indicates immune activation in active vitiligo. Treatment with systemic steroids reduced sICAM-1 levels, suggesting its potential as a marker for disease activity.
Area of Science:
- Immunology
- Dermatology
- Cell Biology
Background:
- Cell surface adhesion molecules mediate crucial intercellular contacts for immune responses.
- Intercellular Adhesion Molecule-1 (ICAM-1, CD54) is vital for cell adhesion in inflammation and cytotoxicity.
- Vitiligo is a condition where immune dysregulation is suspected.
Purpose of the Study:
- To investigate soluble ICAM-1 (sICAM-1) levels in active vitiligo patients.
- To correlate sICAM-1 levels with clinical disease activity and treatment response.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure sICAM-1 serum levels.
- Comparison between healthy controls and active vitiligo patients.
- Correlation analysis with clinical course during systemic steroid therapy.
Main Results:
- Significantly higher average serum sICAM-1 levels were observed in active vitiligo patients compared to healthy controls.
- A significant decrease in sICAM-1 levels was noted after 3 months of systemic steroid treatment in patients who showed clinical improvement.
- These findings indicate a correlation between sICAM-1 levels and disease activity.
Conclusions:
- Immune activation plays a role in the pathogenesis of active vitiligo.
- Serum sICAM-1 levels may serve as a valuable biomarker for monitoring vitiligo activity and treatment efficacy.
Abstract:
Cell surface adhesion molecules are thought to play an important role in establishing intercellular contacts that are necessary for immunological reactions. Intercellular adhesion molecule-1 (ICAM-1, CD54) is a crucial adhesion molecule in mediating cell to cell adhesion during inflammatory responses, including non-MHC-restricted cytotoxicity. In this study, the sICAM-1 levels of ten healthy control subjects and seven generalized active vitiligo patients were measured by ELISA. The sICAM-1 levels were also correlated with the clinical courses in 33 patients with active vitiligo, who received systemic steroid treatment for 3 months. The average serum level of sICAM-1 was significantly higher in patients with active vitiligo than in the healthy control subjects. The sICAM-1 levels significantly decreased after systemic steroid treatment in the clinically improved group. These results suggest that immune activation is involved in active vitiligo and that changes of sICAM-1 levels can be a marker in the course of vitiliginous lesions.